At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7,304 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cost Comparison Between Apixaban and Low Molecular Weight Heparin (LMWH) Among Venous Thromboembolism (VTE) Cancer Patients
In Brief
An observational study for Thromboembolism. Completed, enrolled 7,304 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsThromboembolism
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartAug 2022
First PostedDec 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedDec 9, 2022
Enrollment StartAug 31, 2022
Primary CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.6 years ago